Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Thickett

Showing results (1-10 of 106) with videos related to

Pageof 11
Sort By:
Thorax|March 7, 2013
Pirfenidone for IPF: pro/con debate; the 'con' viewpointGanesh Raghu, David R Thickett
Thorax|May 30, 2014
Authors' response: Epithelial-mesenchymal Transition (EMT) is a common molecular programme in epithelial cells which can be triggered by injuryDomokos Bartis, David R Thickett
Critical Care Medicine|March 27, 2013
Molecular determinants of acute muscle wasting in the ICU: a role for growth and differentiation factor-15?Alice M Turner, David R Thickett
Critical Care Medicine|August 30, 2008
A role for heme oxygenase-1 in alveolar repair after wood smoke exposure?David R Thickett, Gavin D Perkins
American Journal of Respiratory and Critical Care Medicine|November 8, 2002
A role for vascular endothelial growth factor in acute and resolving lung injuryDavid R Thickett, Lynne Armstrong, Ann B Millar
Inflammation & Allergy Drug Targets|June 21, 2013
Vitamin D deficiency and acute lung injuryDhruv Parekh, David R Thickett, Alice M Turner
American Journal of Respiratory and Critical Care Medicine|August 3, 2022
Anti-acid Therapies in Idiopathic Pulmonary Fibrosis: Premature to Dismiss?Louise E Crowley, Andrew Wilson, David R Thickett
Clinical Medicine (London, England)|January 25, 2012
Acute lung injuryDhruv Parekh, Rachel C Dancer, David R Thickett
Thorax|December 4, 2012
Co-trimoxazole for idiopathic pulmonary fibrosis: time for TIPAC-2?Helen Mujakperuo, Emmet E McGrath, David R Thickett
Critical Care (London, England)|April 24, 2015
The increasing need for biomarkers in intensive care unit-acquired weakness--are microRNAs the solution?Sebastian T Lugg, Phillip A Howells, David R Thickett
Pageof 11

Showing results (1-10 of 106) with videos related to

Sort By:
Pageof 11
Thorax|March 7, 2013
Pirfenidone for IPF: pro/con debate; the 'con' viewpointGanesh Raghu, David R Thickett
Thorax|May 30, 2014
Authors' response: Epithelial-mesenchymal Transition (EMT) is a common molecular programme in epithelial cells which can be triggered by injuryDomokos Bartis, David R Thickett
Critical Care Medicine|March 27, 2013
Molecular determinants of acute muscle wasting in the ICU: a role for growth and differentiation factor-15?Alice M Turner, David R Thickett
Critical Care Medicine|August 30, 2008
A role for heme oxygenase-1 in alveolar repair after wood smoke exposure?David R Thickett, Gavin D Perkins
American Journal of Respiratory and Critical Care Medicine|November 8, 2002
A role for vascular endothelial growth factor in acute and resolving lung injuryDavid R Thickett, Lynne Armstrong, Ann B Millar
Inflammation & Allergy Drug Targets|June 21, 2013
Vitamin D deficiency and acute lung injuryDhruv Parekh, David R Thickett, Alice M Turner
American Journal of Respiratory and Critical Care Medicine|August 3, 2022
Anti-acid Therapies in Idiopathic Pulmonary Fibrosis: Premature to Dismiss?Louise E Crowley, Andrew Wilson, David R Thickett
Clinical Medicine (London, England)|January 25, 2012
Acute lung injuryDhruv Parekh, Rachel C Dancer, David R Thickett
Thorax|December 4, 2012
Co-trimoxazole for idiopathic pulmonary fibrosis: time for TIPAC-2?Helen Mujakperuo, Emmet E McGrath, David R Thickett
Critical Care (London, England)|April 24, 2015
The increasing need for biomarkers in intensive care unit-acquired weakness--are microRNAs the solution?Sebastian T Lugg, Phillip A Howells, David R Thickett
Pageof 11